Results 91 to 100 of about 6,308,680 (199)

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

open access: yesMolecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice   +16 more
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

D. Seifried, N. Stark: Energiedienstleistungen

open access: yesTechnikfolgenabschätzung – Theorie und Praxis, 1994
TATuP editorial office
doaj   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

Tisekta d twuriwin n yismawen imaẓlayen deg yimahilen iseklanen : asaka n tezlatin n Ǧamal Ɛellam

open access: yesUssnan
In this article, which explores the use of proper names in Djamel Allam's songs, we will examine this lexical category that lies between two essential domains: linguistics and literature.
Atmane RAHMANI
doaj  

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

open access: yesMolecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff   +11 more
wiley   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

Ticraḍ, gar usemres d wazal n yizamulen i d-mmalent

open access: yesUssnan
This contribution aims to describe the practice of tattooing in some Amazigh regions. It tries to list the different techniques, the actors plus the means used to succeed in this practice which has a high value in the society.
Ourida AISSOU
doaj  

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Tixutert n tmezgunt deg uselmed/almad n tutlayt n tmaziɣt. Amedya: Asif n tisselbi i d-yettwasuɣlen seg taɛrabt.

open access: yesUssnan
Amagrad-a yewwi-d ɣef txutert n uselmed/almad n tutlayt tmaziɣt s umezgun, amedya tamezgunt n Tawfik El-Hakim yettwasuɣlen ilmend n yidles amaziɣ. Tazrawt-a treṣṣa ɣef yinefkan n tsastant i nga s udiwenni d yiselmaden akked temsirin i neḥḍer deg tneɣrit.
Hassiba Kherbouche, Mohammed Agaoua
doaj  

Home - About - Disclaimer - Privacy